# RVTY — Revvity Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** RVTY  
**Sources:** 27  
**Published:** 2026-10-04  
**Canonical:** https://app.k3vl4r.com/research/deep-research-rvty-revvity-inc-catalysts-narrative-risks-6079

---

## Revvity Inc. (NYSE: RVTY) — Point-in-Time Snapshot (as of ~Oct 2–4, 2026)

As of the most recent close (Oct 2, 2026), RVTY traded near **$151** with a market cap of ~$16.9B, up roughly **+57% year-to-date** and **+66% over 12 months** against a 52-week range of $81.22–$158.28 [[9]](https://stockanalysis.com/stocks/rvty/), [[11]](https://tickernerd.com/stock/rvty-forecast/), [[13]](https://stockanalysis.com/stocks/rvty/forecast/), [[18]](https://finance.yahoo.com/quote/RVTY/analyst-insights/). The company (formerly PerkinElmer) is a life sciences and diagnostics provider serving pharma, biotech, academic, and clinical markets [[9]](https://stockanalysis.com/stocks/rvty/), [[19]](https://finance.yahoo.com/quote/RVTY/), [[20]](https://en.wikipedia.org/wiki/Revvity).

## Recent Catalysts (last ~1–3 months)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-rvty-revvity-inc-catalysts-narrative-risks-6079 (free to sign up)._